|
⚲
|
| Keyboard |
| Nuvalent Inc | |
|---|---|
| Ticker | NUVL |
| CIK # | 0001861560 |
| CUSIP | 670703107 |
| Sector | Life Sciences - Pharmaceutical Preparations |
| Address | One Broadway, 14th Floor, Cambridge, MA 02142 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| Nuvalent Inc | 2021-05-12 | 135.0 M | Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0001861560] | 10-K | |
| [0001861560] | 10-Q | |
| [0001861560] | 3 | |
| [0001861560] | 4 | |
| [0001861560] | 8-K | |
| [0001861560] | D | |
| [0001861560] | SC 13D | |
| [0001861560] | SC 13G |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed | % Owned |
|---|---|---|---|
| BlackRock Inc | Nuvalent Inc | [2025-07-17] | 0.0 |
| BlackRock Inc | Nuvalent Inc | [2024-11-08] | 5.6 |
| BlackRock Inc | Nuvalent Inc | [2024-10-24] | 5.6 |
| Vanguard Group Inc | Nuvalent Inc | [2024-02-13] | 5.72 |
| Perceptive Advisors LLC | Nuvalent Inc | [2024-01-02] | 5.1 |
| Paradigm Biocapital Advisors LP | Nuvalent Inc | [2023-10-30] | 5.9 |
| Fairmount Funds Management LLC | Nuvalent Inc | [2022-11-09] | 5.13 |
| Flynn James E | Nuvalent Inc | [2022-02-11] | 45.14 |
| FMR LLC | Nuvalent Inc | [2021-08-10] | 0.0 |
| Bain Capital Life Sciences Fund II LP | Nuvalent Inc | [2021-08-04] | 5.6 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Miller Deborah Ann
Class A Common Stock
|
2026-03-26 | Sell | 940 | $97.50 | 91,650 |
|
Miller Deborah Ann
Class A Common Stock
|
2026-03-26 | Sell | 2,803 | $99.46 | 278,786 |
|
Miller Deborah Ann
Stock Option (Right to Buy) · derivative
|
2026-03-26 | Option exercise | 5,500 | $0.00 | |
|
Miller Deborah Ann
Class A Common Stock
|
2026-03-26 | Option exercise | 5,500 | $6.89 | 37,895 |
|
Miller Deborah Ann
Class A Common Stock
|
2026-03-26 | Sell | 1,757 | $98.21 | 172,555 |
|
Balcom Alexandra
Class A Common Stock
|
2026-03-25 | Sell | 13,700 | $100.16 | 1,372,192 |
|
Balcom Alexandra
Stock Option (Right to Buy) · derivative
|
2026-03-24 | Option exercise | 11,430 | $0.00 | |
|
Balcom Alexandra
Class A Common Stock
|
2026-03-24 | Sell | 2,599 | $95.03 | 246,983 |
|
Balcom Alexandra
Class A Common Stock
|
2026-03-24 | Option exercise | 11,430 | $1.08 | 12,344 |
|
Balcom Alexandra
Class A Common Stock
|
2026-03-24 | Sell | 1,160 | $96.50 | 111,940 |
|
Balcom Alexandra
Class A Common Stock
|
2026-03-24 | Sell | 7,671 | $95.88 | 735,495 |
|
Pelish Henry E
Class A Common Stock
|
2026-03-13 | Sell | 2,597 | $98.83 | 256,662 |
|
Pelish Henry E
Class A Common Stock
|
2026-03-13 | Sell | 1,703 | $99.71 | 169,806 |
|
Pelish Henry E
Class A Common Stock
|
2026-03-13 | Sell | 804 | $97.89 | 78,704 |
|
Pelish Henry E
Stock Option (Right to Buy) · derivative
|
2026-03-12 | Option exercise | 8,456 | $0.00 | |
|
Pelish Henry E
Class A Common Stock
|
2026-03-12 | Sell | 5,505 | $98.44 | 541,912 |
|
Pelish Henry E
Stock Option (Right to Buy) · derivative
|
2026-03-12 | Option exercise | 2,985 | $0.00 | |
|
Pelish Henry E
Class A Common Stock
|
2026-03-12 | Sell | 306 | $99.12 | 30,331 |
|
Pelish Henry E
Class A Common Stock
|
2026-03-12 | Option exercise | 4,125 | $29.33 | 120,986 |
|
Pelish Henry E
Class A Common Stock
|
2026-03-12 | Sell | 24,189 | $97.79 | 2,365,442 |
| showing 20 of 200 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 264 | 77,775,090 |
| 2025-12-31 | 239 | 76,539,976 |
| 2025-09-30 | 199 | 71,388,248 |
| 2025-06-30 | 212 | 69,547,317 |
| 2025-03-31 | 210 | 70,793,966 |
| 2024-12-31 | 220 | 70,612,613 |
| 2024-09-30 | 199 | 70,196,354 |
| 2024-06-30 | 176 | 65,931,406 |
| 2024-03-31 | 185 | 64,563,992 |
| 2023-12-31 | 160 | 64,019,334 |
| 2023-09-30 | 118 | 55,285,402 |
| 2023-06-30 | 112 | 54,715,585 |